pensyarah universiti
institut biologi molekul perubatan ukm (umbi)
m.aimanmohtar@ppukm.ukm.edu.my
Biografi/ Biography :
M. Aiman Mohtar is a Research Fellow at the UKM Medical Molecular Biology Institute (UMBI), The National University of Malaysia. He previously earned his BSc. (Biotechnology) with highest honours from Rochester Institute of Technology, New York and MSc. (Molecular Biology) from University of Pennsylvania, Philadelphia. He completed his PhD in Molecular and Clinical Medicine at Institute of Genetics and Molecular Medicine, University of Edinburgh. His PhD thesis focuses on identification of protein-protein interaction network of an oncogenic ER-resident protein. He has been trained as molecular biologist for more than a decade and has involved in research utilizing cutting- edge laboratory techniques such as CRISPR-Cas9 genome editing tools, fluorescence microscopy, phage display and quantitative proteomics. Aiman’s current research focus is studying protein-protein interaction and tumour cell secretory addiction in AGR2 signalling axis using multi-omics approach and developing therapeutic tools targeting pro-oncogenic molecules. To date, he has secured several UKM, national and international grants.
muhammad-redha abdullah-zawawi, shing cheng tan, m. aiman mohtar, saiful effendi syafruddin, teck yew low, muhammad irfan abdul jalal. (2025). unveiling cancer complexity: machine learning insights into multi-omics data. - . 51 - 69.
ma1gorzata lisowska, erin g. worrall,filip zavadil-kokas, keith charlton, euan murray, m. aiman mohtar, radovan krejcir, vaclav hrabal, jack brydon, ainhoa gonzalez urionabarrenetxea,david g. saliba, mariana grima, umesh kalathiya, petr muller, adam krejci, borivoj vojtesek, kathryn l. ball,2robin fahraeus, david j. argyle, maciej parys, and ted r. hupp. (2025). the development of a canine single-chain phage antibody library to isolate recombinant antibodies for use in translational cancer research. - cell reports methods. 1 - 28.
saiful effendi syafruddin, mohamad aimanuddin mohtar. (2025). crispr diy: step by step genome editing protocols in mammalian cells. - . .
mohamad aimanuddin mohtar. (2025). rewriting the code of life: exploring the power of crispr-cas9. - . .
mohamad aimanuddin bin mohtar. (2025). crispr-mediated agr2 repression reveals esr1-driven transcriptional control in breast cancer cells. - international cancer research symposium 2025 (icrs2025). .
safaa m. naes, sharaniza ab-rahim, musalmah mazlan, saiful effendi syafruddin,m. aiman mohtar, asmaa y. abuhamad, amirah abdul rahman. (2025). crispr/cas9 mediated ent2 gene knockout altered purine catabolic pathway and induced apoptosis in colorectal cell lines. - plos one. 1 - 16.
m. aiman mohtar, siti nur hasanah mohd yusuf, and saiful effendi syafruddin. (2024). cholesterol accumulation in ccrcc: the role of ccrcc-initiating vhl-hifa pathway. - ebiomedicine. 1-2.
nurul nadia mohamad zamberi, asmaa y abuhamad, teck yew low, m aiman mohtar, saiful effendi syafruddin. (2024). dcas9 tells tales: probing gene function and transcription regulation in cancer. - the crispr journal. 73-87.
syazalina zahari, saiful effendi syafruddin and m. aiman mohtar. (2023). impact of the cancer cell secretome in driving breast cancer progression. - cancers. 1-17.
m. aiman mohtar, syazalina zahari, nisa syakila a. rahman, saiful effendi, muhammad-redha abdullah-zawawi, teck yew low, ted hupp. (2023). rna-seq analysis of crispr-cas9 targeted agr2 of breast cancer cells reveals potential modulators of its expression and secretion. - esmo open. 6.
saiful effendi syafruddin, wan fahmi wan mohamad nazarie, nurshahirah ashikin moidu, bee hong soon, m. aiman mohtar. (2021). integration of rna-seq and proteomics data identifies glioblastoma multiforme surfaceome signature. - bmc cancer. 1-13.
nurul nadia mohamad zamberi, siti nur hasanah mohd yusufb m. aiman mohtar, saiful effendi syafruddin. (2025). uncovering the transcription factor network driving klf6 expression through super enhancers in renal cell carcinoma. - asian pacific journal of molecular biology and biotechnology. 17 - 17.
safaa m. naes, sharaniza ab-rahim, musalmah mazlan, saiful effendi syafruddin,m. aiman mohtar, asmaa y. abuhamad, amirah abdul rahman. (2025). crispr/cas9 mediated ent2 gene knockout altered purine catabolic pathway and induced apoptosis in colorectal cell lines. - plos one. 1 - 16.
ma1gorzata lisowska, erin g. worrall,filip zavadil-kokas, keith charlton, euan murray, m. aiman mohtar, radovan krejcir, vaclav hrabal, jack brydon, ainhoa gonzalez urionabarrenetxea,david g. saliba, mariana grima, umesh kalathiya, petr muller, adam krejci, borivoj vojtesek, kathryn l. ball,2robin fahraeus, david j. argyle, maciej parys, and ted r. hupp. (2025). the development of a canine single-chain phage antibody library to isolate recombinant antibodies for use in translational cancer research. - cell reports methods. 1 - 28.
m. aiman mohtar, siti nur hasanah mohd yusuf, and saiful effendi syafruddin. (2024). cholesterol accumulation in ccrcc: the role of ccrcc-initiating vhl-hifa pathway. - ebiomedicine. 1-2.
nurul nadia mohamad zamberi, asmaa y abuhamad, teck yew low, m aiman mohtar, saiful effendi syafruddin. (2024). dcas9 tells tales: probing gene function and transcription regulation in cancer. - the crispr journal. 73-87.
muhammad-redha abdullah-zawawi, shing cheng tan, m. aiman mohtar, saiful effendi syafruddin, teck yew low, muhammad irfan abdul jalal. (2025). unveiling cancer complexity: machine learning insights into multi-omics data. - . 51 - 69.
saiful effendi syafruddin, mohamad aimanuddin mohtar, tan shing cheng, nadiah abu, nor aidatulakma abdullah@muda, nurul syakima ab mutalib, chin siok fong, neoh hui min, rahman jamal, nor azian abdul murad. (2019). umbi initiatives on colorectal cancer biomarkers discovery. - . 19-28.
nurul nadia mohamad zamberi, mohd raziff alias, m. aiman mohtar, saiful effendi syafruddin. (2025). aplikasi teknologi crispr/cas9 dan penyuntingan perdana dalam kajian biologi molekul dan kefungsian gen. - jurnal sains kesihatan malaysia. 67 - 79.
yuh cai chia, sundharavalli ramayah , nurul nadia mohamad zamberi, mohamad aimanuddin mohtar , saiful effendi syafruddin. (2023). crispr/cas9: teknik penyuntingan dan modifikasi gen. - . 1.
mohamad aimanuddin mohtar. (2023). penyuntingan baka secara tidak terkawal lahirkan manusia mutan. - berita harian. 1.
siti nur hasanah mohd yusuf, m. aiman mohtar, saiful effendi syafruddin. (2023). penyahkawalseliaan proses transkripsi dalam patogenesis kanser. - majalah dewan kosmik. 50-53.
mohamad aimanuddin mohtar, saiful effendi syafruddin. (2022). protein agr2: bio penanda baru untuk pengesanan awal kanser. - impak: kluster kesihatan & perubatan termaju. 28-29.
saiful effendi syafruddin, mohamad aimanuddin mohtar. (2025). crispr diy: step by step genome editing protocols in mammalian cells. - . .
mohamad aimanuddin mohtar. (2025). rewriting the code of life: exploring the power of crispr-cas9. - . .
mohamad aimanuddin bin mohtar. (2025). crispr-mediated agr2 repression reveals esr1-driven transcriptional control in breast cancer cells. - international cancer research symposium 2025 (icrs2025). .
mohamad aimanuddin mohtar. (2024). mass spectrometry-based proteomics and gene editing. - introduction of proteomics and metabolomics course. .
m. aiman mohtar, syazalina zahari, saiful effendi syafruddin, low teck yew, ted hupp, tiannan guo. (2024). defining intracellular and extracellular role of agr2: insights from crispr-targeted breast cancer cells and dia-nn analysis. - 23rd human proteome organization world congress. .
| Geran / Grant | Kolaborator / Collaborator | Status |
|---|---|---|
| INVESTIGATING ENGINEERED NANOVESICLE CAPTURING AGENT AGAINST PRO-ANGIOGENIC VEGFA IN RENAL CARCINOMA | genscript biotech (singapore) private limited | 49.7% (2025-03-03 sehingga 2026-03-02) |
| ELUCIDATING THE CROSSTALK BETWEEN HIF2α-VEGFA AND KLF6-PDGFβ AXES IN DRIVING RENAL CARCINOMA HYPERVASCULARIZATION | nanoarms sdn. bhd. | 76.8% (2023-10-01 sehingga 2026-03-31) |
| ELUCIDATING THE CROSSTALK BETWEEN HIF2α-VEGFA AND KLF6-PDGFβ AXES IN DRIVING RENAL CARCINOMA HYPERVASCULARIZATION | genomax technologies sdn bhd | 76.8% (2023-10-01 sehingga 2026-03-31) |